We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher's Biotechnology Growth Picks Up: A Sign of More Upside?
Read MoreHide Full Article
Key Takeaways
Biotech core revenues rose 6% YoY in Q2, led by strong bioprocessing demand.
Orders in bioprocessing are up for eight straight quarters, signaling solid momentum.
Discovery and medical sales declined on weaker research equipment demand.
Danaher Corporation’s (DHR - Free Report) Biotechnology segment continues to play an important role in its overall growth. In the second quarter of 2025, the segment’s core revenues rose 6% on a year-over-year basis, fueled by sustained momentum in the bioprocessing business.
An increase in demand for consumables from large pharmaceutical customers in Western Europe has been aiding the bioprocessing business. Also, solid demand from pharmaceutical customers for monoclonal antibodies (mAbs) augurs well for the business. It is worth noting that, in the second quarter, orders in the bioprocessing business increased for the eighth consecutive quarter. For 2025, DHR anticipates core revenues from the bioprocessing business to increase in high single digits on a year-over-year basis.
However, weakness in the discovery and medical business due to reduced demand for equipment in the life science research end markets is concerning for the Biotechnology segment. Core sales from the discovery and medical business decreased in the low single digits in the second quarter.
Overall, while near-term softness in the discovery and medical business poses a headwind, the recurring demand for products in the bioprocessing business provides a solid foundation for future growth. With approximately 7% year-over-year core revenue increase expected in 2025, the Biotechnology segment remains a key pillar of Danaher’s long-term value creation.
Segment Snapshot of DHR's Peers
Among its major peers, CVS Health Corporation’s (CVS - Free Report) Health Services segment reported net sales of $46.5 billion in the second quarter of 2025, up 10.2% year over year. CVS Health generated 47% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided the segment’s results in the second quarter.
Labcorp Holdings Inc.’s (LH - Free Report) Biopharma Laboratory Services segment generated net sales of $784.8 million in the second quarter of 2025, up 11% year over year. This was driven by Labcorp’s strong drug development capabilities and scientific expertise. Labcorp derived 22.1% of its total revenues from this segment during the quarter.
DHR's Price Performance, Valuation and Estimates
Shares of Danaher have declined 29.3% in the past year against the industry’s growth of 9.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 23.13X, above the industry’s average of 16.37X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DHR’s 2025 earnings has been on the rise over the past 60 days.
Image: Bigstock
Danaher's Biotechnology Growth Picks Up: A Sign of More Upside?
Key Takeaways
Danaher Corporation’s (DHR - Free Report) Biotechnology segment continues to play an important role in its overall growth. In the second quarter of 2025, the segment’s core revenues rose 6% on a year-over-year basis, fueled by sustained momentum in the bioprocessing business.
An increase in demand for consumables from large pharmaceutical customers in Western Europe has been aiding the bioprocessing business. Also, solid demand from pharmaceutical customers for monoclonal antibodies (mAbs) augurs well for the business. It is worth noting that, in the second quarter, orders in the bioprocessing business increased for the eighth consecutive quarter. For 2025, DHR anticipates core revenues from the bioprocessing business to increase in high single digits on a year-over-year basis.
However, weakness in the discovery and medical business due to reduced demand for equipment in the life science research end markets is concerning for the Biotechnology segment. Core sales from the discovery and medical business decreased in the low single digits in the second quarter.
Overall, while near-term softness in the discovery and medical business poses a headwind, the recurring demand for products in the bioprocessing business provides a solid foundation for future growth. With approximately 7% year-over-year core revenue increase expected in 2025, the Biotechnology segment remains a key pillar of Danaher’s long-term value creation.
Segment Snapshot of DHR's Peers
Among its major peers, CVS Health Corporation’s (CVS - Free Report) Health Services segment reported net sales of $46.5 billion in the second quarter of 2025, up 10.2% year over year. CVS Health generated 47% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided the segment’s results in the second quarter.
Labcorp Holdings Inc.’s (LH - Free Report) Biopharma Laboratory Services segment generated net sales of $784.8 million in the second quarter of 2025, up 11% year over year. This was driven by Labcorp’s strong drug development capabilities and scientific expertise. Labcorp derived 22.1% of its total revenues from this segment during the quarter.
DHR's Price Performance, Valuation and Estimates
Shares of Danaher have declined 29.3% in the past year against the industry’s growth of 9.7%.
Image Source: Zacks Investment Research
From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 23.13X, above the industry’s average of 16.37X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DHR’s 2025 earnings has been on the rise over the past 60 days.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.